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a b s t r a c t 
Cisplatin-based chemotherapy is the standard treatment of choice for head and neck squamous cell car- 
cinoma (HNSCC). The efﬁciency of platinum-based therapies is directly inﬂuenced by the development 
of tumor resistance. Multiple signaling pathways have been linked to tumor resistance, including acti- 
vation of nuclear factor kappa B (NF κB). We explore a novel mechanism by which NF κB drives HNSCC
resistance through histone modiﬁcations. Post-translational modiﬁcation of histones alters chromatin 
structure, facilitating the binding of nuclear factors that mediate DNA repair, transcription, and other 
processes. We found that chemoresistant HNSCC cells with active NF κB signaling respond to chemother- 
apy by reducing nuclear BRCA1 levels and by promoting histone deacetylation (chromatin compaction). 
Activation of this molecular signature resulted in impaired DNA damage repair, prolonged accumula- 
tion of histone γH2AX and increased genomic instability. We found that pharmacological induction of 
histone acetylation using HDAC inhibitors prevented NF κB-induced cisplatin resistance. Furthermore, 
silencing NF κB in HNSCC induced acetylation of tumor histones, resulting in reduced chemoresistance 
and increased cytotoxicity following cisplatin treatment. Collectively, these ﬁndings suggest that epi- 
genetic modiﬁcations of HNSCC resulting from NF κB-induced histone modiﬁcations constitute a novel 
molecular mechanism responsible for chemoresistance in HNSCC. Therefore, targeted inhibition of 
HDAC may be used as a viable therapeutic strategy for disrupting tumor resistance caused by NF κB. 
C © 2013 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical 
Societies. All rights reserved. ntroduction 
Chromatin is the state in which DNA is packaged within the cell. 
he nucleosome is the fundamental unit of chromatin, and it is com- 
osed of an octamer of histones (H2A, H2B, H3 and H4) around which 
47 base pairs of DNA are wrapped. In eukaryotes, the chromatin 
tructure profoundly affects replication, transcription, and repair by  This is an open-access article distributed under the terms of the Creative Commons 
ttribution-NonCommercial-ShareAlike License, which permits non-commercial use, 
istribution, and reproduction in any medium, provided the original author and source 
re credited. 
Abbreviations: HNSCC, head and neck squamous cell carcinoma; NF κB, nuclear fac- 
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SA, bovine serum albumin; NIH, National Institutes of Health; siRNA, small interfering 
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ttp://dx.doi.org/10.1016/j.fob.2013.12.003 interfering with the accessibility of DNA to enzymes that carry out 
these processes [ 1 ]. Changes in DNA folding driven by histone acety- 
lation and deacetylation dynamically regulate gene expression, re- 
sulting in alterations of the cellular response to environmental cues. 
Histones are considered molecular markers of epigenetic changes and, 
in combination with their modiﬁers, modulate tumor behavior and 
cellular phenotype [ 2 , 3 ]. However, little is known about how histones 
are modiﬁed in response to genotoxic agents. 
Cisplatin (cis-Diamminedichloroplatinum II) is a chemotherapeu- 
tic agent used in the treatment of a variety of human cancers. The 
mechanism of cisplatin action involves forming covalent platinum- 
DNA adducts that cause DNA damage [ 4 ]. Cisplatin incorporation in 
the genome triggers various cellular responses, including DNA repair, 
inhibition of transcription, cell cycle arrest, and apoptosis, all pro- 
cesses that require remodeling of the structural and dynamic proper- 
ties of chromatin [ 5 ]. Despite new surgical techniques and chemother- 
apy protocols, tumor resistance to cisplatin remains a signiﬁcant chal- 
lenge for head and neck squamous cell carcinoma HNSCC patients. 
Numerous mechanisms underlie chemoresistance, including genetic 
and epigenetic alterations in the cancer cell that may be acquired f European Biochemical Societies. All rights reserved. 
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 during the treatment cycles [ 6 , 7 ]. Additionally, cancer cells may cir-
cumvent treatment by increasing drug inactivation or efﬂux [ 8 –10 ],
disrupting tumor suppressor genes [ 11 ], altering DNA damage repair
(DDR) [ 12 , 13 ], and activating mitogenic signaling pathways, such as
nuclear factor kappa B (NF κB) signaling, that result in reduced apop-
tosis (reviewed in Ben-Neriah et al. [ 14 ]). 
The mammalian NF κB family of proteins is comprised of RelA /
p65, NF κB1, NF κB2, c-Rel, and RelB subunits that form a variety of
dimers to control gene expression downstream of signals elicited by
cytokines, bacterial products, viral expression, growth factors, and
stress stimuli. NF κB is negatively regulated by interacting with the
I κB family of proteins, which prevent DNA binding and promote cy-
toplasmic accumulation of NF κB family members. NF κB is positively
regulated by the I κB kinase (IKK) complex that phosphorylates I κB
proteins and induces their degradation, thereby permitting NF κB to
translocate to the nucleus. Once in the nucleus, NF κB binds to target
DNA sequences and regulates the expression of genes involved in the
immune response, cell growth, and cell survival [ 15 ]. 
We identiﬁed a novel mechanism by which NF κB signaling drives
chemoresistance in HNSCC. We found that NF κB acts as a novel mod-
ulator of chromatin modiﬁcations following cisplatin treatment by
preventing histone acetylation and inducing condensation of tumor
chromatin. Furthermore, NF κB-induced cisplatin resistance was pre-
vented following histone acetylation achieved through the adminis-
tration of HDAC inhibitors or by silencing the NF κB signaling path-
way. 
Results 
Chemoresistant HNSCC cell lines have reduced nuclear size and active 
NF κB signaling 
Patients suffering from advanced stage head and neck tumors are
often treated with a combination of surgery and chemotherapy. Plat-
inum based therapies are considered the standard of care for many
solid tumors, including HNSCC, but the development of chemoresis-
tance is common [ 16 ]. Tumor resistance to chemotherapy is a ma-
jor problem during therapy, especially for patients presenting tumor
spread beyond the primary site. For these patients, chemotherapy
represents the basis of their treatment and is critical in determin-
ing their survival [ 10 ]. We used a heterogeneous panel of HNSCC cell
lines that have varying degrees of sensitivity to cisplatin. In response
to cisplatin, HN13, UMSCC74A and Cal27 had an IC50 of more than
7 μg / ml and were deemed chemoresistant. HN6, UMSCC17B and the
control normal oral keratinocyte (NOK-SI) cell line had an IC50 under
5 μg / ml and were deemed chemosensitive ( Fig. 1 A). Interestingly, the
active subunit of NF κB, as identiﬁed by the phospho-p65 antibody,
was localized in the cytoplasm of cisplatin-sensitive tumor cells and
in the nucleus of cisplatin-resistant cells ( Fig. 1 B). NF κB is activated
following translocation from the cytoplasm to the nucleus where is
functions as a transcription factor and as a pro-survival factor [ 17 ].
Active NF κB promotes HNSCC resistance to chemotherapy and radio-
therapy by preventing tumor cells from undergoing apoptosis [ 18 ].
We found that treating HNSCC cells with cisplatin (5 μg / ml) for 24 h
caused noticeable morphological changes in the nucleus. To charac-
terize this phenotype, we stained tumor cells with Hoechst 33342
and analyzed the nucleus by morphometry. We measured ﬁfty nuclei
from each cell line. Unexpectedly, we found that chemosensitive cells
and normal oral epithelial cells that show a dramatic increase in nu-
clear size following cisplatin treatment (UMSCC 17B, HN6 and NOK-SI
*** , p < 0.001) in contrast to chemoresistant tumor cells that respond
to cisplatin either by reducing the size of their nucleus (UMSCC74A
and HN13 *** , p < 0.001) or maintaining its original size (Cal27) ( Fig.
1 C). These ﬁndings suggest that tumor cells respond to chemotherapy
through alterations in chromatin condensation / decondensation and
organization. Notably, changes in chromatin condensation correlateto decreases or increases in nuclear diameter [ 19 , 20 ]. These ﬁndings
encouraged us to examine the effect of chemotherapy on histones
given that acetylation disrupts the electrostatic interactions between
histone and DNA, resulting in a decrease in chromatin condensation
[ 21 ]. 
Deacetylation of tumor histones is accompanied by reduced levels of 
BRCA1 and enhanced genomic instability in chemoresistant tumor cells 
Chromatin structure is involved in a range of well-characterized
DNA metabolism processes, including replication [ 22 ], transcription
[ 23 ] and DNA damage repair [ 24 ]; however, the role of chromatin
organization in chemoresistance is unknown. To assess whether
changes in nuclear size are associated with chromatin condensa-
tion, we treated HNSCC and control cells with several concentra-
tions of cisplatin (1, 2.5 or 5 μg / ml) for 24 h and analyzed acetyl
histone H3 (Lys9) protein levels ( Fig. 2 A). Dynamic variations in the
organization of chromatin structure are mediated by histone acety-
lation and deacetylation. Following cisplatin exposure, we found that
chemoresistant tumor cells had reduced nuclear size and deacetly-
ation of histone H3 (Lys9), a known marker of chromatin relaxation
( Fig. 2 A Ac.H3) [ 25 , 26 ]. Histone deacetylation is involved in enhanced
histone–DNA interactions and chromatin condensation [ 27 –29 ]. In-
terestingly, cisplatin had no effect on histone H3 levels in chemosen-
sitive and control cells, as evidenced by the similarities to vehicle
control. Of interest to our analysis, functional acetylation of histone
3 at Lys 9 is associated with histone deposition, chromatin assembly,
and gene activation [ 30 –32 ]. 
Chromatin decondensation, also known as decondensation kinet-
ics, is a key mechanism that ensures proper gene transcription and
repair of the genome in which histone acetylation plays a central role
in unwinding of DNA [ 33 ]. Activation of the DNA damage response
machinery triggers chromatin decondensation and access to DNA re-
pair proteins [ 12 ]. Because chromatin organization is essential for the
accessibility of DNA repair molecules, we examined whether cisplatin
affects BRCA1 accumulation and cell death in chemoresistant tumor
cells. Cisplatin (1, 2.5 or 5 μg / ml) treatment for 24 h ( Fig. 2 A) did not
prevent BRCA1 accumulation in HN6 and UMSCC17B chemosensitive
cells. In contrast, chemoresistant cells treated with cisplatin had com-
pacted chromatin evident by reduced levels of acetylated histone 3
( Fig. 2 A Ac.H3) and reduced BRCA1 levels ( Fig. 2 A BRCA1). The pro-
tein encoded by the BRCA1 breast cancer susceptibility gene protects
the genome by activating cell cycle checkpoints and participating in
DNA repair [ 13 ]. Following extensive DNA damage, BRCA1 translo-
cates to the nucleus to induce cell cycle arrest and cell death; how-
ever, dysfunctional BRCA1 enhances genomic instability [ 14 , 34 –36 ].
We found that BRCA1 is localized to the nucleus in chemosensitive tu-
mor cells compared to its cytoplasmic localization in chemoresistant
tumor cells ( Supplementary Fig. S1 – arrow head). Reduced BRCA1
in the nucleus of HNSCC cells correlated with increased genomic in-
stability following 24 h of cisplatin (5 μg / ml) treatment and 24 h
of recovery ( Fig. 2 B). As determined by Comet assay, cisplatin pro-
duced more DNA damage in HN6 cells ( *** p < 0.001) compared to
HN13 cells ( ** p < 0.01). Although HN6 cells are chemosensitive, they
recovered from DNA damage more efﬁciently than HN13 chemoresis-
tant cells ( *** p < 0.001 and NS respectively). To conﬁrm these results,
we assessed recovery of DNA damage in HN6 and HN13 cells using
immunoﬂuorescence and the anti- γH2AX antibody. Histone γH2AX
plays an important role in assembling the DNA damage response com-
plex by identifying DNA double strand breaks (DSB) in the chromatin.
Upon DSB, ATM induces phosphorylation of γH2AX at serine 139, re-
sulting in recruitment of BRCA1, BRCA2, Rad51, Mre11, NBS1, FANCD2
and p53 repair proteins to sites of DNA damage [ 37 , 38 ]. Prolonged
maintenance of phosphorylated γH2AX foci in the chromatin rep-
resents unrepaired DSB, making this molecule a suitable marker for
assessing DNA repair activity and length of time for repair [ 37 , 38 ]. We
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Fig. 1. Cisplatin resistant HNSCC cell lines have NFkB activity and decreased nuclear size. (A) Graphic determination of the inhibitory concentration (IC50) of cisplatin using a cell 
viability assay. NOK-SI, UMSCC17B, HN6, HN13, UMSCC74A and Cal27 cell lines were treated with several concentrations of cisplatin (2.5, 5, 7.5, 10, 12.5, 15, 17.5 and 20 μg / ml) 
for 24 h. (B) Immunoﬂuorescence staining localization of phospho-p65 (p-P65) in NOK-SI, UMSCC 17B, HN6, HN13, UMSCC 74A and Cal27 cells. Arrowheads indicate nuclei without 
p-P65 staining. Note nuclear localization of p-P65 in HN13 and Cal27 cells (arrow). Nuclei were stained with Hoechst 33342 (blue). (C) Graphics depict nuclear size in NOK-SI, 
UMSCC 17B, HN6, HN13, UMSCC 74A and Cal27 cells treated with vehicle or cisplatin (5 μg / ml) for 24 h ( n = 150 cells / condition). Reduced nuclear size was observed in HN13 
( *** p < 0.001), UMSCC 74A ( *** p < 0.001) and Cal27 cells. Increased nuclear size was observed in NOK-SI ( *** p < 0.001), UMSCC 17B ( *** p < 0.001) and HN6. ( *** p < 0.001) (For 
interpretation of the references to color in this ﬁgure legend, the reader is reffered to the web version of this article.) 
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tuantiﬁed γH2AX foci at different time points during DNA damage 
ecovery (5, 10, 15 and 60 min and 6, 12 and 24 h) ( Supplementary Fig. 
2 ). After 5 min, both cell lines had reduced accumulation of γH2AX 
oci, indicating that nearly half of the DSBs were repaired. In con- 
rast, HN6 cells with BRCA1 localized to the nucleus were still in the 
rocess of DNA repair (reduced levels of γH2AX mean 1.15), which 
ad completely failed in HN13 cells (stable levels of γH2AX mean 
.27). Collectively, these ﬁndings support the notion that tumor cells 
esistant to chemotherapy respond to cisplatin through chromatin 
ondensation that prevents access of BRCA1 to sites of DNA damage. 
e still do not know if decondensation of tumor chromatin by histone 
cetylation will improve the cytotoxicity of cisplatin. 
harmacological acetylation of histones sensitizes tumor cells to 
isplatin 
The acetylation process is determined by histone acetyltransferase 
HAT) and histone deacetylase (HDAC) enzyme activities. HATs trans- 
er acetyl groups to lysines in the tail of histones, promoting the 
xpansion of chromatin and increasing accessibility of the DNA. In 
ontrast, HDACs catalyze the removal of acetyl groups, leading to 
hromatin condensation [ 39 ]. Because chemoresistant cells have a 
maller nucleus and reduced histone acetylation following cisplatin 
reatment compared to chemosensitive cells, we decided to induce histone acetylation pharmacologically. We treated HN6 (chemosen- 
sitive) and HN13 (chemoresistant) cells with the trichostatin A (TSA) 
HDAC inhibitor and cisplatin for 24 h and analyzed cell viability by 
MTS. TSA increased cisplatin-induced cytotoxicity in both tumor cell 
lines ( Fig. 3 A). Maximum cytotoxicity was achieved in both cells at 
low doses of cisplatin (5 μg / ml) which become indistinguishable 
from cellular viability achieved by high doses of cisplatin (12.5 μg / 
ml) (ns p > 0.05) compared to HN6 and HN13 tumor cells receiving 
vehicle plus cisplatin ( *** p < 0.001 and ** p < 0.01 respectively). Nu- 
clear staining using Hoechst 33342 revealed increased nuclear size in 
both cell lines in response to TSA ( Fig. 3 A Hoechst 33342). 
We next wanted to determine whether NF κB plays a role in chro- 
matin condensation given that NF κB was activated (nuclear accumu- 
lation) in chemoresistant HN13 cells and inactivated (cytoplasmic 
accumulation) in HN6 cells (chemosensitive). Numerous signaling 
proteins can activate NF κB, including TNF- α, which triggers rapid 
degradation of I κB α that is mediated by TNFR1 and results in nuclear 
accumulation of NF κB [ 27 , 40 ] ( Supplementary Fig. S3 ). We activated 
NF κB in chemosensitive HN6 cells, which normally have low NF κB, 
using TNF- α and treated with cisplatin before staining nuclei with 
Hoechst 33342 ( Fig. 3 B upper panel). Interestingly, activation of NF κB 
alone did not signiﬁcantly affect HN6 chromatin organization, as de- 
termined by nuclear size. However, induction of the NF κB pathway 
using TNF- αpartially blocked cisplatin-induced nuclear decondensa- 
tion ( Fig. 3 B, cisplatin + TNF- α; ** p < 0.01) compared to cisplatin 
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Fig. 2. HNSCC chemoresistance to cisplatin is associated with loss of BRCA1 and chromatin acetylation and failure of the DNA repair machinery. (A) Western blot assay of NOK-SI, 
UMSCC 17B, HN6, HN13, UMSCC 74A and Cal27 cells treated with cisplatin (1, 2.5 and 5 μg / ml) for 24 h and probed with anti-acetyl-H3 and anti-BRCA1 antibodies. GAPDH 
served as a loading control. Note that chemosensitive cells have increased BRCA1 and acetyl-H3, and chemoresistant cells have reduced BRCA1 and acetyl-H3. (B) Representative 
microphotographs of the alkaline comet assay depict DNA fragmentation in response to vehicle and cisplatin treatment. The DNA damage recovery phase was established after 
cisplatin was removed for 24 h. Note the undamaged HN6 and HN13 cells (vehicle; comet head only) and fragmentation of DNA following cisplatin treatment (cisplatin; tail 
formation of the comet). HN6 displayed DNA damage repair (HN6 recovery; comet head only) in contrast to HN13 (HN13 recovery – maintenance of the tail). Comet assay 
quantiﬁcation showed DNA damage in HN6 ( *** p < 0.001) and HN13 ( ** p < 0.01) after cisplatin treatment. Note that HN6 lack DNA fragmentation (no comet tail) after 24 h of 
cisplatin withdrawal ( *** p < 0.001) and HN13 DNA remain fragmented during the entire recovery period (NS p > 0.05). ( n = 200 cell / condition; error bar: mean ± SEM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 alone. 
An active NF κB pathway is often associated with tumor survival
and chemoresistance in many tumors, including HNSCC. However, the
mechanism by which NF κB drives and sustains tumor survival and
enhances tumor resistance remains largely unknown (reviewed in
Karin et al. [ 41 ]). To determine the role of NF κB in cisplatin resistance,
we treated chemosensitive HN6 cells with TNF- α and cisplatin and
assessed cell viability. Interestingly, TNF- α-induced upregulation of
NF κB increased cell viability and abrogated cisplatin toxicity in HN6
cells ( Fig. 3 B – lower panel, *** p < 0.001).  NF κB regulates tumor resistance to chemotherapy by controlling 
chromatin folding and nuclear inﬂux of BRCA1 
We next examined whether disruption of NF κB would affect the
chromatin condensation phenotype observed in chemoresistant cells.
It is well established that NF κB activity is the result of I κB kinase alpha
(IKK α)- and beta (IKK β)-induced phosphorylation of I κB that permits
nuclear transport of NF κB [ 28 , 29 ]. Thus, by interfering with IKK αand
IKK β, I κB α promotes NF κB ubiquitinization and degradation [ 41 ].
We used siRNA directed against IKK α and IKK β to enable I κB to re-
press NF κB in chemoresistant HN13 cells ( Supplementary Fig. S4 ).
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Fig. 3. Chromatin acetylation sensitizes cells to cisplatin and loss of NFkB results in increased nuclear size. (A) HN6 and HN13 cells were treated with Trichostatin A (TSA) for 1 h prior 
to cisplatin administration. Immunoﬂuorescence with Hoechst staining showed that TSA treatment resulted in increased nuclear size in both cell lines (immunoﬂuorescence). MTS 
assay for cellular viability demonstrates enhanced cytotoxicity to cisplatin at 5 and 12.5 μg / ml following co-administration of TSA for 24 h compared to vehicle. Low doses of 
cisplatin (5 μg / ml) accompanied by TSA is sufﬁcient to reduce cellular viability of HN6 and HN13 cells to similar levels observed during administration of 12.5 μg / ml of cisplatin. 
Note increased nuclear size of tumor cells receiving TSA (Hoechst 33342). (B) HN6 cells were treated with cisplatin (5 μg / ml), TNF- α (10 ng / ml), and cisplatin + TNF- α. An 
immunoﬂuorescence assay was performed using Hoechst 33342 to deﬁne nuclear morphometry and cytokeratin 14 delineated cellular morphology. Chemosensitive HN6 cells 
respond to cisplatin treatment through chromatin decondensation ( *** p < 0.001 cisplatin). Chromatin decondensation was impaired by co-administration of TNF- α ( ** p < 0.01). 
Lower panel, HN6 cells, treated with cisplatin (5 μg / ml), TNF- α (10 ng / ml), and cisplatin + TNF- α, were evaluated for cellular viability using MTS assay. HN6 became resistant to 
cisplatin when exposed to TNF- α ( *** p < 0.001). TNF- α (in the absence of cisplatin) did not alter cell viability. 
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tollowing knockdown of IKK α and IKK β, HN13 cells were treated 
ith cisplatin (5 μg / ml) and stained with Hoechst 33342. Surpris- 
ngly, suppression of IKK α and IKK β resulted in increased nuclear 
ize after treatment with cisplatin ( Fig. 4 A upper panel, *** p < 0.001). 
hese results suggest that pharmacological acetylation of histones can 
ct as chemical sensitizers in HNSCC, and that active NF κB signaling 
estricts chromatin decondensation in response to cisplatin. 
We then examined whether suppression of NF κB would prevent 
hemoresistance in HN13 cells. We suppressed IKK α and IKK β ex- 
ression in HN13 cells using siRNA, treated cells for 24 h with cisplatin 
5 and 12.5 μg / ml) and analyzed cell viability. HN13 cells were sensi- 
ized to 5 μg / ml of cisplatin following suppression of IKK α and IKK β
ompared to 12.5 μg / ml of cisplatin when transfected with scramble 
iRNA ( Fig. 4 A lower panel). We next examined whether disruption 
f NF κB signaling alters histone acetylation and induces expression 
f BRCA1. Following suppression of IKK αand IKK βwith siRNA, HN13 
ells were treated with TSA, cisplatin, or vehicle and lysed. Proteins 
ere separated by Western blot and membranes probed for anti- 
c.H3 and anti-BRCA1. GAPDH served as a loading control. Suppres- 
ion of IKK α and IKK β resulted in accumulation of acetyl-histone 3 
nd increased BRCA1 compared to control cells ( Fig. 4 B). Furthermore, 
e analyzed whether NF κB signaling selectively regulate nuclear lev- 
ls of BRCA1 during cisplatin induced DNA damage. Interestingly, al- 
hough cisplatin does not increase accumulation of BRCA1 foci upon administration of scramble siRNA in HN13 chemoresistant cells, dis- 
ruption of NF κB signaling through silencing of IKK α resulted in a 
dramatic accumulation of nuclear BRCA1 ( Fig. 4 C, ** p < 0.01; and 
Supplementary Fig. S5 ). Aligned with these results, overexpression of 
NF κB signaling through administration of TNF- α resulted in reduced 
accumulation of BRCA1 in tumor cells receiving cisplatin while no sta- 
tistical signiﬁcance was observed in the control group with vehicle 
( Supplementary Fig. S6 , cisplatin treated cells: *** p < 0.001; vehicle 
treated cells: ns, p > 0.05). 
Collectively, our results indicate that NF κB plays a role in HN- 
SCC tumor resistance by modulating chromatin organization through 
deacetylation of histones and DNA compaction ( Fig. 5 – ↑ NF κB). 
Changes in chromatin organization disrupt BRCA1 translocation to 
the nucleus, resulting in resistance to cisplatin. Disruption of NF κB 
signaling is sufﬁcient to chemosensitize cells to cisplatin by acetylat- 
ing chromatin and increasing BRCA1 levels ( Fig. 5 – ↓ NF κB). 
Discussion 
Resistance to anticancer drugs represents a major problem for the 
long-term effectiveness of chemotherapy. Deregulation of various ge- 
netic pathways drives drug resistance in cancer cells. Thus, novel ther- 
apeutic interventions that prevent drug resistance are needed. We 
found that cisplatin resistant cells have active NF κB signaling. NF κB 
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Fig. 4. NF κB signaling induces tumor resistance and chromatin remodeling in HNSCC. (A) HN13 cells were treated with cisplatin (5 μg / ml) after suppressing NF κB using small 
interference RNA for IKK α and IKK β. Cellular morphometry denotes increased nuclear size of chemoresistant HN13 cells following siRNA interference. Note that maintenance of 
chromatin deacetylation and condensation, observed in HN13 cells treated with cisplatin, are overcome by small interference RNA for IKK α (siRNA IKK α, *** p < 0.001) and IKK β
(siRNA IKK β, *** p < 0.001). After suppressing NF κB using small interference RNA for IKK α and IKK β in HN13, cells were treated with cisplatin (5 and 12.5 μg / ml) (lower panel). 
IKK α and IKK β knockdown alone did not alter cell viability. However, silencing NF κB sensitized the cells to the cisplatin treatment, as evidenced by reductions in viability in 
response to 5 μg / ml cisplatin (siRNA IKK α * p < 0.05 and siRNA IKK β ** p < 0.01). Note that chemoresistant HN13 cells respond to low doses of cisplatin (5 μg / ml), which is 
equivalent to the IC50 concentration observed initially in HNSCC cells sensitive to cisplatin. (B) Immunoblot analysis of HN13 cells transfected with siRNA Control and siRNA for 
IKK α and IKK β. Cells were treated with vehicle, cisplatin (5 μg / ml), and TSA (100 ng / ml). BRCA1 levels were unchanged following vehicle, cisplatin or TSA treatments. BRCA1 was 
increased following NF κB blockage (siRNA IKK α and siRNA IKK β). Additionally, HN13 cells with blocked NF κB (siRNA for IKK α and IKK β) had abrupt H3 acetylation of chromatin. 
TSA treatment was used as a positive control for H3 acetylation, and GAPDH was used as a loading control. (C) BRCA1 foci formation was accessed upon disruption of NF κB 
signaling. Silencing of IKK α resulted in increased accumulation of BRCA1 foci compared to scramble siRNA treated cells ( ** p < 0.01). Administration of cisplatin resulted in further 
accumulation of BRCA1 foci. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 is retained in the cytoplasm through interaction with its inhibitors
(I κBs). In response to a variety of stimuli, I κBs are phosphorylated by
I κB kinases (IKK) and degraded. This permits NF κB to translocate to
the nucleus where it stimulates the expression of target genes [ 42 , 43 ].
Constitutive activation of NF κB is commonly observed in a variety of
tumor types. Increased NF κB activity is often associated with the de-
velopment of chemoresistance [ 16 , 41 , 44 ]; however, the mechanism
underlying the chemoresistant phenotype is not understood. Recent
advances in tumor biology have identiﬁed nuclear translocation of
NF κB as a suppressive mechanism for programmed cell death. Ad-
ditionally, inhibition of NF κB nuclear transport enhances apoptosis
[ 45 –47 ]. 
Chromatin compaction, gene expression, apoptosis and cellular di-
vision inﬂuence nuclear size [ 20 ]. Chromatin compaction is regulated
via DNA binding proteins and histone modiﬁcations [ 48 ]. Deacety-
lation of histones promotes chromatin compaction, and acetylation
results in chromatin decondensation, permitting accessibility to in-
teracting proteins [ 49 ]. Collectively, changes in nuclear morphology
correlate with global changes in histone acetylation [ 20 ]. We found
that chemoresistant HNSCC cell lines respond to cisplatin treatment
through reduction in nuclear size and histone deacetylation. These
data prompted us to explore the molecular mechanism involved inhistone deacetylation and chromatin compaction given this process
reduces the association of DNA with larger molecules, such as cisplatin
and DNA repair complexes [ 50 ]. We showed that chemoresistant HN-
SCC cells treated with cisplatin had accumulation of DSB, but BRCA1
did not translocate to the nucleus, resulting in increased genomic
instability. These data suggest an epigenetic mechanism by which
tumor cells control chromatin accessibility through histone modi-
ﬁcations. It has been proposed that HDAC proteins regulate NF κB
activity through deacetylase and that chromatin acetylation using
TSA is sufﬁcient to inhibit this activity [ 51 ]. Therefore, it is conceiv-
able that chromatin acetylation plays a role in chemoresistance in a
NF κB-dependent manner. Yet, enhanced NF κB signaling may restrict
its interaction with HDAC proteins, suggesting that highly active NF κB
signaling often found in head and neck tumors may inﬂuence chro-
matin remodeling. Indeed, we found that activation of NF κB through
co-administration of TNF- α and cisplatin in tumor cells resulted in
a substantial reduction in the size of the nucleus, and that inhibi-
tion of NF κB by suppression of IKK α and IKK β resulted in increased
nuclear size and increased acetyl histone 3. In this case, directly tar-
geting NF κB signaling in head and neck tumors inﬂuences chromatin
acetylation and gene transcription. 
The effect of NF κB on chromatin remodeling was a very exciting
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Fig. 5. Proposed mechanism of NF κB-induced chemoresistance in HNSCC. Genotoxic ther- 
apy driven by cisplatin induces chromatin acetylation (Ac.H3) and increased nuclear 
inﬂux of BRCA1. HNSCC cells with low levels of NF κB have reduced cellular viability 
and respond to cisplatin treatment. In contrast, tumor cells with high levels of NF κB 
fail to undergo chromatin acetylation, which is reﬂected in the lack of BRCA1 nuclear 
translocation and resistance to cisplatin chemotherapy. When NF κB is inhibited, cis- 
platin induces chromatin acetylation and nuclear translocation of BRCA1, resulting in 
chemosensitive HNSCC cells. 
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cnding. Interfering with NF κB signaling resulted in chromatin decon- 
ensation and accumulation of BRCA1, potentially due to increased 
vailability of DSBs to protein complexes from the DDR machinery. 
ndeed these ﬁndings led to another exciting result, which was that 
nhibition of NF κB sensitized HNSCC to cytotoxic chemotherapy. We 
o not know if the increased sensitivity to cisplatin following sup- 
ression of IKK α and IKK βwas a direct effect of low levels of NF κB or 
 consequence of chromatin acetylation induced by siRNA interfer- 
nce of the NF κB signaling. Regardless, the effect of NF κB signaling 
n chromatin remodeling is clear and indicates a new therapeutic 
pportunity for patients who have acquired resistance to cisplatin. 
Our ﬁndings demonstrate that NF κB acts as a regulator of chro- 
atin remodeling in HNSCC. This mechanism is triggered by geno- 
oxic insults that result in chromatin deacetylation, increased ge- 
omic instability, and reduced levels of nuclear BRCA1; collectively, 
hese factors confer resistance to HNSCC. Pharmacological inducton of 
hromatin acetylation by HDAC inhibitors, or interference with NFkB 
ignaling, completely ablated tumor resistance to cisplatin. Nonethe- 
ess, reestablishment of BRCA1 was dependent on NF κB silencing. 
hese ﬁndings provide new insights into the role of NF κB in chemore- 
istance in HNSCC. 
aterials and methods 
ell lineages and reagents 
HNSCC cell lines (HN6, HN12, HN13, Cal27, UMSCC17B, and UM- 
CC74A) [ 52 –56 ] and NOK-SI were cultured in DMEM supplemented 
ith 10% fetal bovine serum, 100 units / ml penicillin, 100 μg / ml 
treptomycin, and 250 ng / ml amphotericin B. Cells were maintained 
n a 5% CO 2 -humidiﬁed incubator at 37 
◦C. Cells were treated with Tri- 
hostatin A (TSA; Sigma), cisplatin (Sigma), and TNF- α (PeproTech) 
t the concentrations indicated. HN6, HN12, HN13, UMSCC17B, and 
MSCC74A HNSCC cell lines were kindly provided by Dr. J. Silvio 
utkind (National Institute of Dental and Craniofacial Research, NIH, 
ethesda, MD) after authentication by PCR ampliﬁcation of short tan- 
em repeats to ensure cell identity. Cal27 cells were from the Ameri- 
an Type Culture Collection. I κB kinase (IKK) knockdown 
Knockdown of IKK α and IKK βwas performed in HNSCC cell lines 
as previously described [ 40 ]. Brieﬂy, cells were seeded in 24-well 
plates and transfected with 12.5 nM double-stranded RNA oligonu- 
cleotides directed against human IKK α (NM 001278; forward: 5 ′ - 
CAG GAG AAG UUC GGU UUA GUAdTdT-3 ′ and reverse: 5 ′ - UAC UAA 
ACC GAA CUU CUC CUGdTdT-3 ′ ) and 25 nM double-stranded RNA 
oligonucleotides against IKK β (NM 001556; forward: 5 ′ - CUG GAG 
AAG UAC AGC GAG CAAdTdT-3 ′ and reverse: 5 ′ - UUG CUC GCU GUA 
CUU CUC CAGdTdT-3 ′ ) (Invitrogen). Optimal concentrations and time 
points were determined by dilution curves of siRNA for each target 
and immunoblot analysis [ 40 ]. The sequences of the control negative 
siRNA (Invitrogen) oligonucleotides were as follows: 5 ′ -UUC UCC GAA 
CGU GUC ACG UdTdT-3 ′ and 5 ′ -ACG UGA CAC GUU CGG AGA AdTdT-3 ′ 
[ 40 ]. 
IC50 determination 
We used the CellTiter 96TM AQueous non-radioactive cell pro- 
liferation kit (Promega) to determine the cisplatin concentration 
that inhibited cell proliferation by 50% (IC50). Cell proliferation was 
determined by reduction of MTS (3-(4,5-dimethylthiazol-2-yl)-5- 
(3-carboxymethoxy phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, in- 
ner salt) following the manufacturer’s protocol. In brief, 2500 cells 
were plated into 96-well plates and treated in triplicate with control 
(vehicle) or cisplatin for 24 h. Cells were incubated with MTS at 37 ◦C 
for 4 h, and the results were assessed by absorbance (Bio-Tek EL- 
311, Bio-Tek Instruments) at 490 nm. Chemosensitivity or chemore- 
sistance of HNSCC was determined by comparison with normal oral 
keratinocytes IC50. Tumor cell lines presenting higher IC50 then NOK- 
SI (5 μg / ml) were considered chemoresistant, while similar or lower 
IC50 were considered chemosensitive. 
Cell viability 
The Rapid Colorimetric MTS assay (Promega) was used to measure 
HNSCC cell viability and proliferation following treatment. The assay 
detects metabolically active viable cells and was performed according 
to manufacturer’s instructions. 
Comet assay 
After treatment, HNSCC cells were embedded in 0.75% low- 
melting point agarose and allowed to solidify on glass slides. Cells 
were then placed in lysis buffer (2.5 M NaCl, 100 mM EDTA and 10 mM 
Tris; pH 10.0–10.5) containing fresh 1% (v / v) Triton X-100 and 10% 
(v / v) dimethyl sulfoxide (DMSO) for 1 h. Following exposure to alka- 
line buffer (300 mM NaOH and 1 mM EDTA; pH > 13) for 20 min, DNA 
was electrophoresed using 25 V (0.90 V / cm) and 300 mA. The slides 
were neutralized in 400 mM Tris (pH 7.5) and stained with Hoechst 
33342 (Invitrogen). Cells were analyzed using the TriTek CometScore 
TM software (TriTek). Three output parameters were measured, in- 
cluding the percentage of tail DNA, tail length, and the tail moment. 
Tail moment was used for statistical analysis [ 57 , 58 ]. 
Immunoﬂuorescence and morphometric assay 
Cells were placed on glass coverslips in 12-well plates and ﬁxed 
with absolute methanol at −20 ◦C for 5 min. Cells were blocked with 
0.5% (v / v) Triton X-100 in PBS and 3% (w / v) bovine serum albumin 
(BSA) and incubated with anti-Acetyl-Histone H3 (Lys9) (Cell Signal- 
ing), anti-BRCA1 (C-20) (Santa Cruz Biotechnology), anti-NF κB p65 
(Santa Cruz Biotechnology), anti-phospho-NF κB p65 (Ser536) (Cell 
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 Signaling) or anti-phospho-Histone H2A.X (Ser139) (Millipore) anti-
bodies as indicated. Cells were then washed three times and incu-
bated with FITC or TRITC-conjugated secondary antibody and stained
with Hoechst 33342 for visualization of DNA content. Images were
taken using a QImaging ExiAqua monochrome digital camera at-
tached to a Nikon Eclipse 80i Microscope (Nikon, Melville, NY) and
visualized with QCapturePro software. For the morphometric assay,
cells were incubated with Hoechst 33342 and anti-Keratin 14 anti-
body (Covance) and measured using the AxioVision 4.8.1 software
measuring tools (Carl Zeiss, Thornwood, NY). Grayscale images were
captured separately after ﬂuorescence excitation using FITC HYQ and
TRITC HYQ ﬁlters. The total number of cells was quantiﬁed using
grayscale images captured from Hoechst 33342, γH2AX, BRCA1, or
acetyl-histone H3 staining. 
Immunoblotting 
Cells were harvested at indicated times, treated with RIPA buffer,
and brieﬂy sonicated. Protein lysates (30 μg) were separated by 10%
to 15% SDS–PAGE and transferred to a polyvinyl diﬂuoride membrane
(Immobilon) (Millipore). Membranes were blocked in 0.1 M Tris (pH
7.5), 0.9% NaCl and 0.05% Tween-20 (TBS-T) with 5% nonfat dry milk.
Membranes were incubated with anti-Acethyl-Histone H3 (Lys9) (Cell
Signaling) and anti-BRCA1 (C-20) (Santa Cruz Biotechnology) primary
antibodies and secondary antibodies conjugated to horseradish per-
oxidase. GAPDH (Calbiochem) served as a loading control. The reac-
tion was visualized using ECL SuperSignal West Pico Substrate (Pierce
Biotechnology). 
Statistical analysis 
All statistical analysis was performed using GraphPad Prism
(GraphPad Software, San Diego, CA). Statistical analysis of the
Comet assay, γH2AX and BRCA1 stains were performed by one-
way analysis of variance (ANOVA) followed by Tukey’s multiple
comparison tests. Nuclear morphometry analyses were performed
by one-way ANOVA followed by Newman-Keuls multiple compar-
ison test. Cellular viability was assessed by two-way ANOVA fol-
lowed by the Bonferroni posttest. BRCA1 nuclear staining was per-
formed by Student’s t -test. Asterisks denote statistical signiﬁcance
( * p < 0.05; ** p < 0.01; *** p < 0.001; and NS p > 0.05). 
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